Trial reportBritish journal of clinical pharmacology2005
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients.
Trial report in British journal of clinical pharmacology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Comparative effect of antihypertensive drugs in improving arterial stiffness in adults with hypertension (RIGIPREV study). A network meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Effect of spironolactone on vascular stiffness in hemodialysis patients: a randomized crossover trial.Upsala journal of medical sciences · 2022Trial
- Effect of Spironolactone on Exercise Tolerance and Arterial Function in Older Adults with Heart Failure with Preserved Ejection Fraction.Journal of the American Geriatrics Society · 2017Trial
- Low dose-eplerenone treatment decreases aortic stiffness in patients with resistant hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2017Trial
- Serum aldosterone is associated with inflammation and aortic stiffness in normotensive overweight and obese young adults.Clinical and experimental hypertension (New York, N.Y. : 1993) · 2012Trial
- Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles.Diabetologia · 2008Trial
- Effect of Dapagliflozin on Myocardial Fibrosis After STEMI: A Double-Blind, Placebo-Controlled Randomized Trial.Journal of clinical medicine · 2026Article
- Article
- The role of pulmonary arterial stiffness in COPD.Respiratory medicine · 2015Review
- Future Treatment of Hypertension: Shifting the Focus from Blood Pressure Lowering to Arterial Stiffness Modulation?Current hypertension reports · 2015Review
- Diabetes impairs the vascular effects of aldosterone mediated by G protein-coupled estrogen receptor activation.Frontiers in pharmacology · 2015Article
- Vascular stiffening in pulmonary hypertension: cause or consequence? (2013 Grover Conference series).Pulmonary circulation · 2014Article
- Effects of Various Antihypertensive Drugs on Arterial Stiffness and Wave Reflections.Pulse (Basel, Switzerland) · 2013Review
- An innovative piezoelectric-based method for measuring pulse wave velocity in patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2011Article
- Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.Journal of cellular and molecular medicine · 2010Review
- Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study.Circulation · 2009Article
- Biomarkers and surrogate endpoints.British journal of clinical pharmacology · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess whether spironolactone has beneficial effects on blood pressure (BP), N-terminal propeptide of type III procollagen (PIIINP) and pulse wave velocity (PWV) in hypertensive, type II diabetics.
methodsTen patients with type II diabetes and hypertension were enrolled in a randomized, double-blind crossover study comparing 4 months' treatment with spironolactone and placebo with a 4-week washout phase. BP, PIIINP and carotid-radial PWV were measured at the end of each treatment phase.
resultsCompared with placebo, spironolactone reduced systolic BP by 15.6 +/- 46.1 mmHg (P = 0.005, 95% CI 2.7-28.5 mmHg), PIIINP by 0.6 +/- 0.3 microg l(-1) (P = 0.04, 95% CI 0.02-1.1 microg l(-1)) and PWV by 0.6 +/- 0.2 m s(-1) (P = 0.008, 95% CI 0.18-1.02 m s(-1)).
conclusionsSpironolactone is effective at reducing systolic BP and brachial artery stiffness as indicated by PWV. It also reduces PIIINP in type II diabetic patients with hypertension.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.